Expression of CD44 standard and variant isoforms v5, v6 and v7 in human ovarian cancer cell lines

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 1871-1876

  Stickeler, Elmar ^a,b   Runnebaum, Ingo B ^b   Möbus, Volker J ^b   Kieback, Dirk G ^a   Kreienberg, Rolf ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Alternative splicing; CD44; CD44 splicing pattern; Ovarian cancer

Indexed keywords

HERMES ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY;

ALTERNATIVE RNA SPLICING; ARTICLE; ASCITES; CANCER CELL CULTURE; CONTROLLED STUDY; EXON; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR;

ANTIGENS, CD; ANTIGENS, CD44; CELL LINE; EXONS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0030769358     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kohn E: Aging issues in invasion and metastasis. Cancer suppl 71: 552-557, 1993.
2. Stamenkovic I, Amiot M, Pesando JM and Seed B: A lymphocyte molecule implicated in lymph node homing is a member of cartilage link protein family. Cell 56: 1057-1062, 1989.
3. Underhill C: CD44: The hyaluronan receptor. J Cell Science 103: 293-298, 1992.
4. Merzak A, Koocheckpour S and Pilkington J: CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Research 54: 3988- 3992, 1994.
5. Stamenkovic I, Aruffo M, Amiot M and Seed B: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate bearing cells. EMBO 10: 343-348, 1991.
6. Sy MS, Guo YJ and Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 174: 859-866, 1991.
7. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P and Zoller M: Participation in normal immune response of splice variant of CD44 that encodes a metastasis inducing domain. Science 257: 682-685, 1992.
8. Fox S, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL,Gearing A and Simmons DL: Normal tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Research 54: 4539-4546, 1994.
9. Bartolazzi A, Peach R, Aruffo A and Stamenkovic I: Interaction between CD44 and hyaluronat is directly implicated in the regulation of tumor development. J Exp Med 180: 53-66, 1994.
10. East JA and Hart IR: CD44 and its role in tumor progression and metastasis. Lancet: 1921-1922, 1993.
11. Günthert U, Hofmnann M, Rudy W, Reber S, Zöller M, Haußmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24, 1991
12. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I and Johnson JP: De-novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019- 1022, 1992.
13. Wielenga VJM, Heider KH, Offerhaus JA, Adolf GR, van den Berg FM, Ponta H, Herrlich P and Pals S: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756, 1993.
14. Joensuu H, Klemi P, Toikkanen S and Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Path 143: 867-874, 1993.
15. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H and Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615-619, 1995.
16. Cannistra S, DeFranzo B, Niloff J and Ottensmeier C: Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res 1: 333-342, 1995.
17. Mackay C, Terpe HJ, Stauder R, Marston WL, Stark H and Gunthert U: Expression and modulation of CD44 variant isoforms in humans.J Cell Biol 124: 71-82, 1994.
18. Cannistra S, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J and Ottensmeier C: CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 13: 1912-1921, 1995.
19. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A and Kainz Ch: Immunhistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 72: 1494-1497, 1995.
20. Uhl-Steidel M, Muller-Holzner E, Zeimet A, Adolf G, Daxenbichler G, Marth C and Dapunt O: Prognostic value of CD44 splice variant expression in ovarian cancer. Oncology 52: 400-406, 1995.
21. Mobus VJ, Asphal WE, Knapstein PG and Kreienberg R: Effects of interferon on the proliferation and modulation of cell surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 120: 27-34, 1993.
22. Mobus VJ, Gerharz CD, Press U, Moll R, Beck T, Meilin W, Pollow K, Knapstein PG and Kreienberg R: Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int. J Cancer 52: 76-84, 1994.
23. Cannistra S, Kansas G, Niloff J, DeFranzo B, Kim Y and Ottensmeier C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Resarch 53: 3830-3838, 1993.
24. Lesley J, Hyman R and Kincade PW: CD44 and its interaction with extracellular matrix. Adv in Immunology 54: 271-335, 1993.
25. Rudy W, Hofmann M, Schwarz-Albiez R, Zöller M, Heider K, Ponta H and Herrlich P: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53: 1262-1268, 1993.
26. Caceres JF, Stamm S, Helfman DM and Krainer AR: Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors. Science 256: 1706-1709, 1994.